Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Human C1 Esterase Inhibitor (Ruconest) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the US

Next Previous
X
Search
Trial Profile

Recombinant Human C1 Esterase Inhibitor (Ruconest) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the US

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Acute lung injury; COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms PROTECT-COVID-19-US
  • Sponsors Pharming Group NV

    • Most Recent Events

    • 02 Jun 2022 Status changed from recruiting to completed.
    • 13 Sep 2021 According to a Pharming Group NV media release, the company will analyze the full results as it will design future clinical trials with RUCONEST for the treatment of COVID-19, as well as other serious conditions.
    • 13 Sep 2021 According to a Pharming Group NV media release, study has been concluded and results will be published in peer-review medical journals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top